# Hsin Tse

> Hsin Tse is a Series D investor at Sino Biopharmaceutical backing Biopharma. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Sino Biopharmaceutical](https://shizune.co/investors/profile/sino-biopharmaceutical)
- Total investments: 2
- Last investment: Jun 2022
- Lead investor: 50%
- Last updated: Aug 2026

Hsin Tse is an executive director and a vice president at Sino Biopharmaceutical.

## Contacts

5 contacts available for Hsin Tse: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/hsin-tse?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 2 | 100% |
| Biotechnology | 2 | 100% |
| Health Care | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 1 | 50% |
| Venture - Series Unknown | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 1 | 50% |
| Singapore | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Evive Biotech | Evive Biotech develops biological therapies for oncology and inflammatory disorders. The company uses proprietary technology platforms to advance drug candidates. It also manages drug development, regulatory compliance, and commercial-scale manufacturing for biologics. | $70M | Venture - Series Unknown | Jun 02, 2022 |  |
| Akeso Biopharma | The company has built a global level of bio-pharmaceutical research and development and industrialization platform; established for cancer, autoimmune diseases, inflammation and cardiovascular disease of the rich product line. The scale of the company's platform, hardware and software facilities, the number of new drug product lines, R &D team in the country are the same industry-leading level. Kang Fang biological has been with the international and domestic listed pharmaceutical companies to establish a cooperative relationship, the joint development of innovative antibodies to new drugs, is a strategic cooperation in the form of development of new drugs in the forerunner. | $150M | Series D | Nov 04, 2019 |  |

2 of 2 investments shown.

## Co-investors
- [Apricot Capital](https://shizune.co/investors/profile/apricot-capital-ceb8) — VC Fund, 1 deal together
- [BOCOM International](https://shizune.co/investors/profile/bocom-international) — VC Fund, 1 deal together
- [CCB Capital](https://shizune.co/investors/profile/ccb-capital) — VC Fund, 1 deal together
- [CDG International Company](https://shizune.co/investors/profile/cdg-international-company) — VC Fund, 1 deal together
- [K. Wah Group](https://shizune.co/investors/profile/k-wah-group) — VC Fund, 1 deal together
- [Lake Bleu Capital](https://shizune.co/investors/profile/lake-bleu-capital) — VC Fund, 1 deal together

## About Sino Biopharmaceutical

VC Fund · Wan Chai, Hong Kong

Sino Biopharmaceutical engages in pharmaceutical products which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemicalmedicines for treating tumours, liver diseases, cardio-cerebral diseases, analgesia, respiratory system diseases and orthopedicdiseases.

3 contacts available at Sino Biopharmaceutical.

| Name | Title | Profile |
| --- | --- | --- |
| Hsin Tse | Executive Director and VP | https://shizune.co/investors/profile/hsin-tse |
| Ping Tse | Founder & Sr. Vice Chairman | https://shizune.co/investors/profile/ping-tse |
| Yi Li | President & CEO | https://shizune.co/investors/profile/yi-li-aab3 |

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Hsin Tse invest in?

Hsin Tse invests primarily in Biopharma, Biotechnology and Health Care startups, most often at Series D and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Hsin Tse?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Hsin Tse last invest?

The most recent investment recorded for Hsin Tse closed in Jun 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co